Does Immunotherapy Have a Role in the Management of Endometriosis?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03464799|
Recruitment Status : Not yet recruiting
First Posted : March 14, 2018
Last Update Posted : March 14, 2018
Kanuni Sultan Suleyman Training and Research Hospital
Information provided by (Responsible Party):
Hale GOKSEVER CELIK, Kanuni Sultan Suleyman Training and Research Hospital
Pathological specimens of 40 women that had been operated for endometriosis will be included in this study. These tissues will be stained with a marker named as PDL-1 in pathological examination. "programmed cell death (PD-1)" is expressed on T cells. The immunotherapies in which antibodies against these PD-1 and its ligands (PDL-1) have been used are accepted as very effective in the treatment of many cancers. If these ligands can be shown in the endometriosis, it will be an important step for the treatment of endometriosis.
|Condition or disease||Intervention/treatment|
|Endometriosis||Other: immunohistochemical staining|
40 women who had been operated for endometriosis between 2013 and 2014 will be included in this study. Pathological specimens will be stained with an immunohistochemical marker named as PDL-1. "programmed cell death (PD-1)" is a protein containing 288 aminoacids and expressed on T cells. It was shown on apoptotic cells in earlier times, but then it has been understood that its physiologic role is not cell death. The upregulation of PD-1 is a result of the activation of T cells and it is necessary for the termination of immune response. PD-L1 is a ligand for PD-1. The immunotherapies in which antibodies against these PD-1 and its ligands (especially PDL-1) provides significant improvements in many cancers such as melanoma. Evidence about the role of these ligands in endometriosis will be an important step in its management.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Does Immunotherapy Have a Role in the Management of Endometriosis?|
|Estimated Study Start Date :||March 2018|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||August 2018|
- Other: immunohistochemical staining
Primary Outcome Measures :
- immunohistochemical staining [ Time Frame: 6 months ]immunohistochemical staining with PD-L1
No Contacts or Locations Provided